NEUROONE MEDICAL TECHNOLOGIE (NMTC) Stock Fundamental Analysis

NASDAQ:NMTC • US64130M2098

0.68 USD
-0.03 (-3.95%)
Last: Feb 20, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

NMTC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. NMTC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NMTC is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year NMTC has reported negative net income.
  • NMTC had a negative operating cash flow in the past year.
  • NMTC had negative earnings in each of the past 5 years.
  • In the past 5 years NMTC always reported negative operating cash flow.
NMTC Yearly Net Income VS EBIT VS OCF VS FCFNMTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M -10M

1.2 Ratios

  • With a Return On Assets value of -33.38%, NMTC is not doing good in the industry: 61.08% of the companies in the same industry are doing better.
  • With a Return On Equity value of -50.91%, NMTC perfoms like the industry average, outperforming 50.81% of the companies in the same industry.
Industry RankSector Rank
ROA -33.38%
ROE -50.91%
ROIC N/A
ROA(3y)-136.43%
ROA(5y)-122.52%
ROE(3y)-579.77%
ROE(5y)-399.07%
ROIC(3y)N/A
ROIC(5y)N/A
NMTC Yearly ROA, ROE, ROICNMTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 -1K -1.5K -2K

1.3 Margins

  • The Gross Margin of NMTC (67.30%) is better than 72.97% of its industry peers.
  • NMTC's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for NMTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.79%
GM growth 5YN/A
NMTC Yearly Profit, Operating, Gross MarginsNMTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • NMTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NMTC has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, NMTC has more shares outstanding
  • Compared to 1 year ago, NMTC has an improved debt to assets ratio.
NMTC Yearly Shares OutstandingNMTC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
NMTC Yearly Total Debt VS Total AssetsNMTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

2.2 Solvency

  • NMTC has an Altman-Z score of -3.72. This is a bad value and indicates that NMTC is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of NMTC (-3.72) is worse than 63.78% of its industry peers.
  • A Debt/Equity ratio of 0.18 indicates that NMTC is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.18, NMTC is in line with its industry, outperforming 59.46% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z -3.72
ROIC/WACCN/A
WACC10.42%
NMTC Yearly LT Debt VS Equity VS FCFNMTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M -10M

2.3 Liquidity

  • NMTC has a Current Ratio of 4.44. This indicates that NMTC is financially healthy and has no problem in meeting its short term obligations.
  • NMTC's Current ratio of 4.44 is fine compared to the rest of the industry. NMTC outperforms 72.97% of its industry peers.
  • A Quick Ratio of 3.47 indicates that NMTC has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.47, NMTC is in the better half of the industry, outperforming 69.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.44
Quick Ratio 3.47
NMTC Yearly Current Assets VS Current LiabilitesNMTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • NMTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 80.49%, which is quite impressive.
  • Looking at the last year, NMTC shows a very strong growth in Revenue. The Revenue has grown by 250.35%.
  • Measured over the past years, NMTC shows a very strong growth in Revenue. The Revenue has been growing by 44.35% on average per year.
EPS 1Y (TTM)80.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-150%
Revenue 1Y (TTM)250.35%
Revenue growth 3Y78.7%
Revenue growth 5Y44.35%
Sales Q2Q%-11.62%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.39% on average over the next years. This is quite good.
  • NMTC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.46% yearly.
EPS Next Y-97.62%
EPS Next 2Y-18.43%
EPS Next 3Y17.39%
EPS Next 5YN/A
Revenue Next Year26.51%
Revenue Next 2Y29.26%
Revenue Next 3Y38.46%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
NMTC Yearly Revenue VS EstimatesNMTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 5M 10M 15M 20M
NMTC Yearly EPS VS EstimatesNMTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NMTC. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NMTC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NMTC Price Earnings VS Forward Price EarningsNMTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NMTC Per share dataNMTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2

4.3 Compensation for Growth

  • NMTC's earnings are expected to grow with 17.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-18.43%
EPS Next 3Y17.39%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • NMTC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NEUROONE MEDICAL TECHNOLOGIE

NASDAQ:NMTC (2/20/2026, 8:00:01 PM)

0.68

-0.03 (-3.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-17
Earnings (Next)05-11
Inst Owners33.27%
Inst Owner Change-3.23%
Ins Owners4.14%
Ins Owner Change-0.55%
Market Cap34.29M
Revenue(TTM)12.10M
Net Income(TTM)-3.60M
Analysts85
Price Target2.35 (245.59%)
Short Float %0.17%
Short Ratio0.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.57%
Min EPS beat(2)1.96%
Max EPS beat(2)41.18%
EPS beat(4)4
Avg EPS beat(4)56.43%
Min EPS beat(4)1.96%
Max EPS beat(4)158.82%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.09%
Min Revenue beat(2)-8.62%
Max Revenue beat(2)8.81%
Revenue beat(4)2
Avg Revenue beat(4)2.41%
Min Revenue beat(4)-43.22%
Max Revenue beat(4)52.66%
Revenue beat(8)3
Avg Revenue beat(8)-18.29%
Revenue beat(12)5
Avg Revenue beat(12)-0.85%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.37%
PT rev (3m)3.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.29%
EPS NY rev (1m)3.13%
EPS NY rev (3m)-6.9%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.83
P/FCF N/A
P/OCF N/A
P/B 4.85
P/tB 4.88
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0.24
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.38%
ROE -50.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.3%
FCFM N/A
ROA(3y)-136.43%
ROA(5y)-122.52%
ROE(3y)-579.77%
ROE(5y)-399.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.79%
GM growth 5YN/A
F-Score6
Asset Turnover1.12
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.22%
Cap/Sales 0.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.44
Quick Ratio 3.47
Altman-Z -3.72
F-Score6
WACC10.42%
ROIC/WACCN/A
Cap/Depr(3y)90.88%
Cap/Depr(5y)118.7%
Cap/Sales(3y)5.1%
Cap/Sales(5y)11.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-150%
EPS Next Y-97.62%
EPS Next 2Y-18.43%
EPS Next 3Y17.39%
EPS Next 5YN/A
Revenue 1Y (TTM)250.35%
Revenue growth 3Y78.7%
Revenue growth 5Y44.35%
Sales Q2Q%-11.62%
Revenue Next Year26.51%
Revenue Next 2Y29.26%
Revenue Next 3Y38.46%
Revenue Next 5YN/A
EBIT growth 1Y64.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y73.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.23%
OCF growth 3YN/A
OCF growth 5YN/A

NEUROONE MEDICAL TECHNOLOGIE / NMTC FAQ

What is the fundamental rating for NMTC stock?

ChartMill assigns a fundamental rating of 3 / 10 to NMTC.


Can you provide the valuation status for NEUROONE MEDICAL TECHNOLOGIE?

ChartMill assigns a valuation rating of 0 / 10 to NEUROONE MEDICAL TECHNOLOGIE (NMTC). This can be considered as Overvalued.


What is the profitability of NMTC stock?

NEUROONE MEDICAL TECHNOLOGIE (NMTC) has a profitability rating of 1 / 10.


What is the earnings growth outlook for NEUROONE MEDICAL TECHNOLOGIE?

The Earnings per Share (EPS) of NEUROONE MEDICAL TECHNOLOGIE (NMTC) is expected to decline by -97.62% in the next year.